Adage Capital Partners Gp, L.L.C. Aclaris Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 9,627,304 shares of ACRS stock, worth $17.9 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
9,627,304
Previous 9,627,304
-0.0%
Holding current value
$17.9 Million
Previous $14.7 Million
7.19%
% of portfolio
0.02%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding ACRS
# of Institutions
98Shares Held
87.6MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN14.3MShares$26.5 Million15.31% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$16.5 Million2.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.66MShares$12.4 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.77MShares$8.87 Million0.46% of portfolio
-
Decheng Capital LLC Menlo Park, CA4.04MShares$7.52 Million1.45% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $124M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...